Month: March 2025

BOSTON, March 03, 2025 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Monday, March 10, 2025 at 2:20 PM EST at the Leerink Partners Global Healthcare Conference in Miami, Florida. A live webcast and replay of the fireside chat will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com. About Pyxis Oncology, Inc.Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination...

– Eton expects to significantly expand patient access to this critical treatment for Wilson disease patients –– $0 co-pay for all eligible patients and best-in-class patient support services –– Now available exclusively through Optime Care – DEER PARK, Ill., March 03, 2025 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has launched Galzin® (zinc acetate) capsules. Galzin is FDA-approved for the maintenance treatment of patients with Wilson disease who have been initially treated with a chelating agent. It is the only FDA-approved zinc therapy for Wilson disease. “We are excited to launch Galzin with our dedicated sales force and robust Eton Cares patient support...

Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero days All participants in CHAPTER-1 OLE who had reached week 62 reported improved health-related quality of life Ongoing RAPIDe-2 extension study includes efficacy data from seven upper airway, including laryngeal, attacks; median time to onset of symptom relief was 0.9 hours (N=7) In both extension studies, deucrictibant was generally well tolerated with no safety signals observedZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE)...

ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that its management will participate in the Leerink Partners Global Healthcare Conference 2025, taking place from March 10-12, 2025, at the W South Beach Hotel in Miami, FL. Details are as follows:Format: Fireside ChatRepresentative:  Berndt Modig, CEO of PharvarisDate & Time:  Monday, March 10, 9:20 a.m. ET   A live audio webcast will also be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations....